1-Boc-4-甲基哌啶置于palladium On Activated Charcoal 盐酸,四甲基乙二胺,氢气,仲丁基锂,三乙胺体系中,用 乙醚,乙醇,二氯甲烷,溶剂黄146,乙酸乙酯 作为反应溶剂,-90.0~20.0 °C,101.33 Kpa 条件下,反应 20.0H,反应生成 阿加曲班 参考文献:A Short Synthesis Of Argatroban 标题:A Short Synthesis Of Argatroban 摘要:Argatroban Was Synthesized In Seven Steps From 4-Methylpiperidine. The Condensation Of (+/-)-Trans-Benzyl 4-Methyl-Pipecolic Acid Ester With N-Alpha-Boc-N-Omega-Nitro-L-Arginine Led To Two Diastereomers That Were Separated. One Of Them Is The Precursor Of Argatroban. (C) 2001 Elsevier Science Ltd. All Rights Reserved. DOI:10.1016/s0960-894X(01)00351-1
专利号:US-9994526-B2 优先权日:2011-04-04 标 题 :Process intermediates and methods for the preparation of process intermediates for the synthesis of argatroban monohydrate 发明人:STIVANELLO MARIANO; HUBER FLORIAN ANTON MARTIN; RICCI ANTONIO 权利人:LUNDBECK PHARMACEUTICALS ITALY S P A 摘要:Methods are provided for the synthesis of key intermediates for the synthesis of Argatroban monohydrate, ethyl (2R,4R)-1-[(2S)-2-amino-5-[[imino(nitroamino)methyl]amino]-1-oxopentyl]-4-methylpiperidine-2-carboxylate compounded with HCl. Such intermediates are also provided.
专利号:US-9630923-B2 优先权日:2013-07-09 标题:Biocatalyzed synthesis of the optically pure (R) and (S) 3-methyl-1,2,3,4-tetrahydroquinoline and their use as chiral synthons for the preparation of the antithrombic (21R)- and (21S)-argatroban 发明人:GRISENTI PARIDE 权利人:EUTICALS SPA; EUTICALS SPA 摘要:The present invention relates to the biocatalyzed synthesis of enantiomerically pure (3R) and (3S)-methyl-1,2,3,4-tetrahydroquinoline. Said enantiomerically pure compounds are useful as chiral synthons in organic synthesis and, in particular, for the preparation of diastereomerically pure (21R) and (21S)-agratroban and its analogs. New compounds used as intermediates in the process of the invention are also disclosed.
专利号:US-8378106-B2 优先权日:2008-04-07 标题:Method for preparing argatroban monohydrate and a process for its synthesis 发明人:ZANON JACOPO; LIBRALON GIOVANNA; NICOLE ANDREA 权利人:LUNDBECK PHARMACEUTICALS ITALY S P A; ZANON JACOPO; LIBRALON GIOVANNA; NICOLE ANDREA 摘要:A method is described for preparing argatroban monohydrate obtained from (2R,4R)-1-[N G -nitro-N 2 -(3-methyl-8-quinolinesulphonyl)-L-arginyl]-4-methyl-2-piperidine carboxylic acid by suitably treating crude argatroban. The method either comprises preparation of argatroban monohydrate in a continuous step or an intermediate step of isolating a purified argatroban. Also obtainable from argatroban monohydrate is anhydrous argatroban, shown to have new physico-chemical characteristics. n The described argatroban synthesis and purification process hence enables three different forms of argatroban, not previously described, to be obtained, each with distinctive physico-chemical characteristics and in particular enables argatroban monohydrate to be obtained with high yield and with high purity, being therefore a product suitable for use as active principle in proprietary medicines.
专利号:US-2014088310-A1 优先权日:2011-04-04 标 题 :Process intermediates and methods for the preparation of process intermediates for the synthesis of argatroban monohydrate
专利号:CA-2831987-C 优先权日:2011-04-04 标 题 :Method for the preparation of process intermediates for the synthesis of argatroban monohydrate
专利号:CA-2960667-A1 优先权日:2011-04-04 标题:Method for the preparation of process intermediates for the synthesis of argatroban monohydrate
1: Bain J, Meyer A. Comparison of bivalirudin to lepirudin and argatroban in patients with heparin-induced thrombocytopenia. Am J Health Syst Pharm. 2015 Sep 1;72(17 Suppl 2):S104-9. doi: 10.2146/sp150018. doi: 10.1186/s13054-015-1109-0. 3: McAlister RK, Ito S. Minimal Prolongation of Prothrombin Time with Extended Exposure to Argatroban. Pharmacotherapy. 2015 Jul;35(7):e122-6. doi: 10.1002/phar.1613. Epub 2015 Jul 3. doi: 10.1159/000357866. Epub 2014 Apr 8. doi: 10.1055/s-0034-1398382. Epub 2015 Jan 16. doi: 10.1186/s13019-015-0214-0. 7: Wada T, Yasunaga H, Horiguchi H, Matsubara T, Fushimi K, Nakajima S, Yahagi N. Outcomes of Argatroban Treatment in Patients With Atherothrombotic Stroke: Observational Nationwide Study in Japan. Stroke. 2016 Feb;47(2):471-6. doi: 10.1161/STROKEAHA.115.011250. Epub 2015 Dec 15. doi: 10.1177/1060028014562949. Epub 2014 Dec 16. doi: 10.1016/j.jtcvs.2013.11.051. Epub 2013 Dec 31. doi: 10.1016/j.annfar.2014.06.006. Epub 2014 Aug 20. Review. French. Review. doi: 10.2146/ajhp140258. Erratum in: Am J Health Syst Pharm. 2017 May 15;74(10 ):629. doi: 10.1186/s13054-014-0588-8.
合成参考文献
参考文献:10.2165/11535500-000000000-00000 摘要:Unno Y, Katayama M, Shimizu H. Does functional outcome in acute ischaemic stroke patients correlate with the amount of free-radical scavenger treatment A retrospective study of edaravone therapy. Clin Drug Investig. 2010;30(3):143–55. doi: 10.2165/11535500-000000000-00000. 参考文献:10.1007/s11239-010-0454-8 摘要:Lopes RD, Garcia D, Becker RC, Granger CB, Newby LK, Alexander JH, Jolicoeur EM, Handler A, Pieper KS, Carvalho AC, Guimaraes HP, Chamone DAF, Baruzzi AC, Machado FS, Timerman A, Lopes AC. Highlights from the II international symposium of thrombosis and anticoagulation (ISTA), October 22–23, 2009, São Paulo, Brazil. Journal of Thrombosis and Thrombolysis. 2010 Feb 16;29(4):395–408. doi: 10.1007/s11239-010-0454-8. 参考文献:10.1007/s12028-011-9591-y 摘要:Watanabe M, Siddiqui FM, Qureshi AI. Incidence and management of ischemic stroke and intracerebral hemorrhage in patients on dabigatran etexilate treatment. Neurocrit Care. 2012 Feb;16(1):203–9. doi: 10.1007/s12028-011-9591-y. 参考文献:10.1007/s00701-011-1084-4 摘要:Saito A, Shimizu H, Fujimura M, Inoue T, Tominaga T. Predictive role of modified clinical diffusion mismatch in early neurological deterioration due to atherothrombotic ischemia in the anterior circulation. Acta Neurochir (Wien). 2011 Nov;153(11):2205–10. doi: 10.1007/s00701-011-1084-4.